Your fact-checks will appear here
The topic of Alzheimer's disease treatments is mentioned as a comparison to FTD, highlighting the FDA's recent approval of disease-modifying antibodies for early AD.
Two categories of reliable, FDA‑approved treatments exist for Alzheimer’s disease today: longstanding symptomatic therapies that can modestly improve cognition or behavior, and a new class of anti‑amy...
Proven treatments for Alzheimer’s disease fall into two camps: modest symptomatic drugs that have been used for decades (cholinesterase inhibitors and memantine) and newer anti-amyloid immunotherapies...
There is no evidence in the provided reporting that any regulator‑approved supplement can modify the biological progression of frontotemporal dementia (FTD); multiple clinical reviews and advocacy gro...
Two families of peer‑reviewed, routinely cited treatments exist today: symptomatic agents (cholinesterase inhibitors and memantine) that modestly improve cognition or behavior, and more recently devel...
The FDA now recognizes two classes of treatments for Alzheimer’s: disease‑modifying, amyloid‑targeting monoclonal antibodies that can modestly slow clinical decline in early disease, and older symptom...